CVS Health (NYSE:CVS – Get Free Report) had its price objective lowered by analysts at Royal Bank Of Canada from $113.00 to $108.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the pharmacy operator’s stock. Royal Bank Of Canada‘s price target would indicate a potential upside of 19.87% from the company’s previous close.
Several other research firms also recently weighed in on CVS. Piper Sandler set a $106.00 price target on CVS Health in a research note on Friday. Leerink Partners reduced their price objective on shares of CVS Health from $112.00 to $104.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Barclays lowered their target price on shares of CVS Health from $108.00 to $107.00 and set an “overweight” rating on the stock in a report on Thursday, November 5th. Finally, UBS Group dropped their target price on shares of CVS Health from $118.00 to $107.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. Twenty-three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $107.33.
View Our Latest Analysis on CVS
CVS Health Price Performance
Shares of CVS Health stock traded up $0.74 during trading hours on Monday, hitting $90.09. The company’s stock had a trading volume of 1,218,461 shares, compared to its average volume of 8,582,075. The company has a market cap of $115.27 billion, a PE ratio of 10.49, a PEG ratio of 0.78 and a beta of 0.58. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85. The business has a 50 day moving average price of $89.65 and a two-hundred day moving average price of $89.09. CVS Health has a 12-month low of $69.51 and a 12-month high of $110.68.
CVS Health (NYSE:CVS – Get Free Report) last released its earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $0.44. The firm had revenue of $108.40 billion during the quarter, compared to analysts’ expectations of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $1.60 earnings per share. Analysts expect that CVS Health will post 8.26 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, EVP Prem Shah purchased 23,855 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was bought at an average cost of $83.89 per share, with a total value of $2,001,195.95. Following the completion of the purchase, the executive vice president owned 88,516 shares in the company, valued at approximately $7,425,607.24. This represents a 36.89% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.
Institutional Trading of CVS Health
Hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in CVS Health during the 2nd quarter valued at $12,747,462,000. State Street Corp increased its holdings in shares of CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after acquiring an additional 15,604,883 shares during the period. Wellington Management Group LLP increased its holdings in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after acquiring an additional 11,233,381 shares during the period. Bank of America Corp DE raised its position in shares of CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock worth $2,398,868,000 after acquiring an additional 13,836,701 shares in the last quarter. Finally, Pzena Investment Management LLC bought a new position in shares of CVS Health in the 2nd quarter worth $1,217,558,000. 80.66% of the stock is owned by hedge funds and other institutional investors.
CVS Health Company Profile
CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.
Further Reading
- Five stocks we like better than CVS Health
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
